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Abstract
Background: Antiretroviral treatment (ART) in children has special features and consequently, results
obtained from clinical trials with antiretroviral drugs in adults may not be representative of children.
Nelfinavir (NFV) is an HIV-1 Protease Inhibitor (PI) which has become as one of the first choices of PI for
ART in children. We studied during a 3-year follow-up period the effects of highly active antiretroviral
therapy with nelfinavir in vertically HIV-1 infected children.
Methods: Forty-two vertically HIV-infected children on HAART with NFV were involved in a multicentre
prospective study. The children were monitored at least every 3 months with physical examinations, and
blood sample collection to measure viral load (VL) and CD4+ cell count. We performed a logistic
regression analysis to determinate the odds ratio of baseline characteristics on therapeutic failure.
Results: Very important increase in CD4+ was observed and VL decreased quickly and it remained low
during the follow-up study. Children with CD4+ <25% at baseline achieved CD4+ >25% at 9 months of
follow-up. HIV-infected children who achieved undetectable viral load (uVL) were less than 40% in each
visit during follow-up. Nevertheless, HIV-infected children with VL >5000 copies/ml were less than 50%
during the follow-up study. Only baseline VL was an important factor to predict VL control during follow-
up. Virological failure at defined end-point was confirmed in 30/42 patients. Along the whole of follow-up,
16/42 children stopped HAART with NFV. Baseline characteristics were not associated with therapeutic
change.
Conclusion: NFV is a safe drug with a good profile and able to achieve an adequate response in children.
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Background
The introduction of highly active antiretroviral therapy
(HAART) has lead to a significant decrease in mortality
and disease progression in HIV-1 infected children and
adolescents [1,2]. Antirretroviral treatment (ART) in chil-
dren has special features and consequently, results
obtained from clinical trials in adults may not be repre-
sentative of children and more studies about ART effec-
tiveness in the paediatric age are needed.
Nelfinavir (NFV) is an HIV-1 Protease Inhibitor (PI).
When combined with other antiretroviral drugs, it has
been associated with immunologic and virologic
responses in antiretroviral therapy-naïve and experienced
adults and children with a good tolerance profile [3,4].
The challenge to give it weigh twice daily instead of the
previous schedule of three times per day [5,6] and the
weaker relationship between NFV and changes on metab-
olism, have become NFV as a good choice for ART in chil-
dren [7]. However further analysis, like our study, to
assess the association between baseline characteristics and
virological or therapeutical failures are needed.
Methods
Population and study design
This is a multicentre prospective study on a cohort of 42
vertically HIV-infected children on HAART with NFV
recruited between May 1997 to October 2001, and fol-
lowed-up until October 2004 in 5 Spanish hospitals. This
study was conducted according to the declaration of Hel-
sinki and approved by the Ethical Committees of all hos-
pitals involved.
The inclusion criteria were: a) VL >1,000 copies/mL at
baseline, b) at least 6 months of follow-up, c) starting
HAART for the first time with nelfinavir (25–35 mg/Kg,
three times per day), d) having received mono or dual
nucleoside therapy before starting HAART. e) No CD4+
cell count and age restrictions. All vertically HIV infected
children in Madrid are enrolled in the same cohort, which
has 276 patients. We selected those patients who started
HAART with NFV, 72 out of 276. Nevertheless, from these
72 infants, 42 had previous treatment and 14 were naïve.
We selected only the 42 experienced children in this
study.
The children were monitored under a standardized form
at least every 3 months with physical examinations, and
serial measurements of CD4+ T-cells and VL as described
below [8]. There was not a uniform approach regarding
antiretroviral treatment in the background regimen given
together with NFV. During the follow-up we recorded all
the clinical events and side effects related to the use of
NFV.
VL was measured in plasma using the Amplicor Monitor
assay. (Amplicor monitor, Roche Diagnostic Systems,
Brandenburg, NJ, USA). The limit of quantification
(LOQ) was 400 copies/mL. Adherence was measured by
each clinician by pill count methods and interviews with
parents or tutors.
Statistical analysis
Analysis of data was performed by on-treatment analysis
of observed data. Data from patients who were lost to fol-
low-up were censored during the last visit. Endpoint for
therapeutical failure was defined as any of the following:
a) failure to reduce VL < 1 log10 during the first 12 weeks
of HAART, unless it was < lower LOQ; and b) failure to
achieve a VL < LOQ after 24 weeks of HAART. c) change
of NRTI or additional NNRTI or PI in HAART regimen
during the first 24 months of follow-up, while taking
NFV; d) Stop of HAART with NFV during the first 24
months of follow-up. We performed a multivariate logis-
tic regression analysis to determinate the odds ratio (OR)
of baseline characteristics (%CD4+, VL, and age at base-
line, previous ART protocol, and new drugs in HAART reg-
imen) on therapeutical failure.
Moreover, we also consider as therapeutic failure during
the whole follow-up: a) achieve a decrease of 1 log10 VL,
unless it was < lower LOQ; b) achieve VL < LOQ. c)
change of NRTI or additional NNRTI or PI in HAART; d)
stop of HAART with NFV. e) rebound of two consecutive
VL ≥ LOQ after achieving a VL < LOQ. This treatment fail-
ure was analyzed by Kaplan-Meier method and multivari-
ate Cox regression analyses to assess the hazard ratio (HR)
values of baseline characteristics.
All tests were two-tailed with P-values < 0.05 considered
significant. Statistical analysis was performed by SPSS
12.0 software (SPSS INC, Chicago, IL, USA).
Results
Characteristics of HIV-1-infected children
During the study period (median: 41 (min: 6; max: 71.3)
months), a total of 42 children with previous ART started
HAART with NFV (Table 1). More than 50% of those chil-
dren had diagnosis of AIDS previous to baseline; 29/42 of
children had CD4+ T-cells <25% whereas 14/42 had VL
>50.000 copies/ml.
The HAART protocol used was 2 NRTI plus NFV and 28/
42 of children changed NRTI in first line of HAART,
because all of them have taken previous NRTI regimens.
Virological and immunological response
A very important increase in CD4+ was observed and VL
decreased quickly and sustained (Figure 1A). Children
with CD4+ <25% at baseline had a CD4+ recovery andBMC Infectious Diseases 2006, 6:107 http://www.biomedcentral.com/1471-2334/6/107
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they achieved CD4+ >25% 9 months of follow-up, but
these children did not achieve similar values of CD4+
than children with CD4+ ≥25% at baseline (Figure 1B).
However, we did not find differences in VL control
between them (data not shown). Moreover, HIV-infected
children who achieved uVL (≤400 copies/ml) were less
than 40% during follow-up (Figure 1C). Nevertheless,
HIV-infected children with VL >5000 copies/ml were less
than 50% during the follow-up study (Figure 1C).
In this follow-up study, 38/42 children achieved a
decrease in VL < 1 log10 and 28/42 children achieved uVL
anytime during follow-up (Figure 2A). The median time
to achieve a decrease in -1 log10 VL was 3 ± 0.64 months,
and to achieve uVL was 12.4 ± 4.87 months.
Only baseline VL and previous ART protocol [Combined
therapy (CT) or Mono-therapy (MT)] were important fac-
tors to predict VL control during follow-up. The HR of
baseline VL to achieve uVL was 0.33 (CI95%: 0.16; 0.68;
p = 0.003) per log10 VL at baseline and HR of previous ART
protocol (CT vs. MT) to achieve uVL was 0.18 (CI95%:
0.05; 0.69; p = 0.013). HIV-infected children with VL
>50,000 copies/mL at baseline had a negative likelihood
of 3.34 (CI95%: 1.15; 9.67; p = 0.014) to achieve uVL.
After achieving uVL, 17/28 children had a rebound of VL
>400 copies/ml with a mean time of 17.7 ± 6.4 months
(Figure 2B).
Moreover, 19/42 children changed of NRTI or additional
NNRTI or PI in HAART regimen in the first line of HAART,
with a mean of time of 30.4 ± 1.32 months. Besides, 16/
42 children stopped HAART with NFV with a mean of
time of 27.4 ± 1.7 months by Kaplan-Meier method (Fig-
ure 2C). Baseline characteristics were not associated with
therapeutic change.
Endpoint of therapeutical failure
Virological failure at defined end-point was confirmed in
30/42 patients. Besides, 20/42 children had virological
failure defined as a reduction in VL <1 log10 during the
first 12 weeks of HAART; and 25/42 children had virolog-
ical failure to achieve a VL < LOQ after 24 weeks of
HAART. When these 3 criteria of virological failure were
used combined, we only found that baseline VL had a
value of OR of 3.76 (CI95%: 1.13; 12.47; p = 0.03) per
log10 and VL >50,000 copies/mL at baseline had a value of
OR of 8.57 (CI95%: 1.31; 56.3; p = 0.025) to achieve a VL
< LOQ after 24 weeks of HAART.
On HAART with NFV, 9/42 children changed of NRTI or
additional NNRTI or PI in HAART regimen during the first
24 months of follow-up and 15/42 children stopped
HAART with NFV during the first 24 months of follow-up.
Clinical events
Among all patients, one child died and two children
developed AIDS during the follow-up. Only four patients
experienced side effects; diarrhoea in two patients, rash
and hypertransaminasemia in one infant and hypercho-
lesterolemia in other child.
The adherence of the antiretroviral drugs was measured by
each paediatrician by examination of the dose taken by
each child and through interviews with their parents or
tutors. Overall, the adherence was >90% among all the
infants included in our study during the follow-up.
Besides, HAART with NFV was well tolerated.
Discussion
Our study reveals that NFV is a safe drug with a good pro-
file and active to achieve an adequate response in HIV-1
infected children. NFV, like other PI, is highly active in
Table 1: Characteristics of clinical, immunological, and 
virological parameters, and antiretroviral treatment of vertically 
HIV-1-infected children.
Previous-ART
N. of HIV-children 42
Age (years)(a) 6.7 ± 0.64 (0.5; 16.1)
Male(b) 16 (38.1%)
AIDS diagnosis (CDC)(b) 23 (54.7%)
Baseline CD4+cell count
% CD4+(a) 23.2 ± 1.8 (0.8; 49.7)
15 – 25% CD4+(b) 13 (22%)
<15 % CD4+(b) 16 (27.1%)
Baseline HIV-RNA level
log10 VL (copies/mL)(a) 4.52 ± 0.11 (3.22; 6.84)
VL >50,000 copies/mL(b) 14 (33.3%)
ART with NRTI prior-HAART(b)
Monotherapy 39 (92.9%)
Therapy combined 3 (7.1%)
HAART regimen at baseline(b)
3TC + d4T + NFV 27 (64.3%)
AZT + 3TC + NFV 6 (14.3%)
d4T + ddI + NFV 9 (21.49%)
New NRTI on HAART
0 NRTI 14 (33.3%)
1 NRTI 14 (33.3%)
2 NRTI 14 (33.3%)
HAART regimen during follow-up(b)
Global adherence (>90%) 100%
Change of drugs on first line of HAART 9 (21.4%)
Change of NRTI 2 (4.8%)
Adding a NNRTI 4 (9.5%)
Adding a PI 3 (7.1%)
Stop of HAART with NFV 16 (38.1%)
Change of NFV by other PI 12 (28.6%)
Interruption of HAART 4 (9.5%)
Values are expressed as: a) mean ± s.e.m. (min; max), and b) absolute 
(percentage). VL: viral load; CDC: Center for Disease Control. 
HAART: highly active antiretroviral therapy.BMC Infectious Diseases 2006, 6:107 http://www.biomedcentral.com/1471-2334/6/107
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vitro, therefore its activity in vivo is limited by their rapid
clearance [9]. Pharmacologic enhancement of PI with low
doses of ritonavir (RTV) has been shown to increase drug
concentrations [10]. The combination of lopinavir (LPV)
and RTV, has been widely used on paediatric patients and
it has demonstrated a great activity, even higher as those
reported with NFV [11]. Nevertheless, LPV/RTV was not
approved for administration to paediatric patients when
our study was started [12]. Moreover, the lipid abnormal-
ities and insulin resistance reported in adults with LPV/
RTV with an unknown effect on children [13,14], the
availability of a palatable form of NFV and the report of
higher cross-resistance when LPV/RTV is used in a first line
of HAART, has lead to an extensive use of NFV in paediat-
ric age [15].
We recruited 42 infants who were not naïve to antiretrovi-
ral drugs. Nevertheless, NFV showed high efficacy in
increasing the CD4+ cell count and early decreasing of VL
among the three years of follow-up. Our results are similar
to other studies which evaluate NFV efficacy among chil-
dren [4,16].
The presence of higher virologic failures at the end of our
study, 71.4% compared with data published with adults,
have been shown in previous analysis because children
have higher VL and require longer times to achieve an uVL
Summary of Kaplan-Meier curves of HIV-infected children on HAART during follow-up Figure 2
Summary of Kaplan-Meier curves of HIV-infected children on HAART during follow-up. A: to achieve VL <400 copies/ml for 
the first time or to achieve a decrease of -1 log10 VL. B: rebound of viral load after achieving VL ≤400 copies/ml. C: to change 
NRTI or additional NNRTI or PI in HAART regimen in the first line of HAART; or stop HAART with nelfinavir.
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[17]. Furthermore, our study recruit a high number of
children older than 3 years, 74%, who have been taken
ART for long periods of time and whose rates of virologic
failure were higher that those reported in infant under 3
years, (77% vs. 56%). Besides, regarding to the unpredict-
ability plasma concentrations of NFV that have been
reported [6], the lack of therapeutic drug monitoring
(TDM) measurement and analysis in a normal cohort
(not in clinical trial) could have reduced the effectiveness
in our study.
During the three years, 45% change the line of HAART
and 38% interrupt NFV. These patients have similar char-
acteristics at baseline so the use of a resistance test may
have allowed selecting the most appropriate NRTI for
each patient. Moreover, at baseline only 1/3 of children
included 2 new NRTI in HAART line and 1/3 did not take
any new NRTI. High virologic failure at the end of our
study is probably due to previous resistance mutations to
NRTI. Besides, new NNRTI or PI were added as second
HAART line and some patients changed NRTI during the
follow-up. However, the global tendency of VL was not
improved which could be explained by the appearance of
new resistance mutations to NRTI or cross resistance to PI.
It is probable that if a resistance assay would have been
used to guide changes of ART, virological response would
have been higher.
Our study reveals that NFV is safe because only four
patients experienced side effects. These results are consid-
erably minor than other studies that reveal gastrointesti-
nal side effects related to the use of NFV in 18% patients
[18]. On each follow-up visit only 40% achieve uVL.
However, 90% have a decreased in VL >1 log10 and 70%
have an uVL during the three years follow-up. Only VL at
baseline was an important factor to predict VL control
during the follow-up, as others studies have also shown
[8].
Conclusion
In conclusion, when selecting an antiretroviral combina-
tion we need to consider short and long toxicities, as well
as the immunologic, virologic and clinical benefit that a
patient can achieve. Our results show that NFV is an effec-
tive and well tolerate drug for HIV infection among chil-
dren. However, more studies which include
measurements as TDM or resistance test are needed to
evaluate the use of this drug in paediatric population.
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